Olympus

Potential benefits

• Supports libido^{1, 5}
• Aids in sexual receptivity¹
• Formulated to support rapid onset of arousal^{1, 4}
• Promotes erection quality and sensitivity¹
• May help address premature ejaculation^{1, 3}
• Flexible dosing options for varied lifestyles

• The medication is designed to work when there is an initial sexual stimulus
• Dose adjustments should aim for the lowest appropriate dose to potentially mitigate adverse effects, support adherence and based on response as determined by the prescriber

Adverse Effects

• Nausea^6,7
• Flushing⁷
• Headache⁷
• Dizziness⁷
• Reduction in heart rate⁷
• Increase in blood pressure⁷
• Uterine contraction (in postpartum women)⁶

Serious Adverse Effects

• Hyperpigmentation⁷

Contraindications

• Not suitable for individuals with history of cardiovascular disease⁷

Handling requirements

• Keep away from children and pets

Olympus combines oxytocin and bremelanotide to support sexual wellness in men and women. Oxytocin is a natural hormone that plays a role in bonding, intimacy, and sexual arousal. When taken under the tongue, it can help activate areas of the brain linked to attraction and sexual interest. This may help address feelings of connection and make it easier for the body to respond during sexual activity. Bremelanotide works mainly in the brain. It activates melanocortin 4 receptor (MC4R) that help promote sexual desire and arousal. By activating these receptors, it may help patients reach sexual excitement and support their overall experience. Together, these ingredients work on the brain through different mechanism to help support a healthy sexual response.^1-5

Q: How long does it take to see a response? 

A: TTypical onset has been observed within 30 minutes after taking. If no effect is seen, you may need to increase your dose up to a max of 1 full tablet per 24 hours as recommended by your prescriber.

Q: Can I use this with other medications? 

A:It may be used with other medications. Always consult your prescribing healthcare provider before combining with other medications.

Q: What if I miss a dose? 

A: This medication is designed to be used as needed 30 minutes prior to sexual activity. There is no need to take it as a daily dosing unless directed by your prescriber.

Q: Why does bremelanotide cause hyperpigmentation in patients using it for sexual dysfunction?

A:Bremelanotide activates melanocortin receptors that are located in the brain and melanocytes located in the skin. The activation of melanocytes in the skin will increase melanin production and cause darkened patches of skin or gums in some patients. This hyperpigmentation is typically seen on the face, and gums the risk is higher in people with darker skin tones. In some cases, the discoloration may not fully resolve after stopping the medication, so patients are advised to stay within labeled dosing limits and to contact their clinician if they notice new or worsening dark spots while using bremelanotide.⁸

IMPORTANT INFORMATION ABOUT COMPOUNDED MEDICATIONS
This medication has been compounded (custom-prepared) by a pharmacy.
This compounded preparation:
- Has not been approved by the FDA
- Has not undergone FDA review for safety, effectiveness, or quality
- Is prepared specifically for you based on your prescriber's order
- Individual outcomes may vary
Compounded medications are not subject to FDA approval and lack the same safety and efficacy data as FDA-approved commercial medications.
This medication should be prescribed and monitored by a licensed healthcare professional familiar with the condition being addressed and the specific applications of the medication.

1. Melis MR, Argiolas A. Oxytocin, Erectile Function and Sexual Behavior: Last Discoveries and Possible Advances. Int J Mol Sci. 2021 Sep 26;22(19):10376. doi: 10.3390/ijms221910376. PMID: 34638719; PMCID: PMC8509000.
2. Oti T, Sakamoto H. Neuropeptidergic control circuits in the spinal cord for male sexual behaviour: Oxytocin-gastrin-releasing peptide systems. J Neuroendocrinol. 2023 Sep;35(9):e13324. doi: 10.1111/jne.13324. Epub 2023 Jul 29. PMID: 37515539.
3. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild- to- moderate erectile dysfunction. Int J Impot Res. 2004 Feb;16(1):51-9. doi: 10.1038/sj.ijir.3901139. PMID: 14963471.
4. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 Nov;134(5):899-908. doi: 10.1097/AOG.0000000000003500. PMID: 31599840; PMCID: PMC6819021.
5. Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020 Jul;54(7):684-690. doi: 10.1177/1060028019899152. Epub 2020 Jan 1. PMID: 31893927.
6. Oxytocin. Prescribing information. DailyMed. National Library of Medicine. Revised January 12, 2025. Accessed February 26, 2026
7. Bremelanotide. Prescribing information. DailyMed. National Library of Medicine. Revised November 13, 2025. Accessed February 26, 2026
8. VYLEESI [package insert]. Bridgewater, NJ: Cosette Pharmaceuticals, Inc.; 2024.